At-Home Prescription Drug Disposal System
At-Home Prescription Drug Disposal System
批准号:
8751814
负责人:
BADAWI DWEIK
金额:
$14.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-08-30 至 2014-03-03
关键词:
7,7&apos-dimethoxy-(4,4&apos-bi-1,3-benzodioxole)-5,5&apos-dicarboxylic acid dimethyl esterChemical StructureChemicalsCost AnalysisDevelopmentDevice DesignsDevicesDrug PrescriptionsEffectivenessElectrodesEquipmentEvaluationFrequenciesGenerationsGuidelinesHome environmentHouseholdLiquid substanceOxidantsPerformancePharmaceutical PreparationsPharmacologic SubstancePhaseProcessSafetySolidSpecific qualifier valueStructureSystemTechnologyVicodinWaterXanaxZoloftcost effectivedesignminiaturizeoperationprototypescale upuser-friendly
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Objective: Demonstrate effectiveness of a safe, immediate, cost-effective, ecological, and user-friendly system that enables at-home deactivation and disposal of psychoactive prescription pharmaceuticals. Giner, Inc. proposes to develop a miniaturized electrolytic mixed-oxidant (MOX) system to safely destroy psychoactive pharmaceuticals in solid, liquid or patch form. The proposed system is designed to temporarily attach to a standard household faucet to eliminate need for extra equipment and to achieve size, performance and safety advantages over existing technologies. Phase I will assess overall feasibility of concept by focusing on design of MOX reactor and identifying requirements to inactivate selection of highly used pharmaceutical drugs. Phase I focus on following Specific Aims:
1. Design, Fabricate and Assemble BDD/MOX System Components. Focus on development/fabrication of compact and functional electrolytic MOX reactor unit by designing electrode structure and assembling necessary components.
2. Characterize Key Process Variables and Parameters. Process variables and parameters will be identified and optimized for sufficient electro-generation of mixed oxidants to inactivate select pharmaceutical products.
3. Demonstrate Suitable Performance of the System on Select Pharmaceuticals. Performance of proposed system will be assessed using psychoactive pharmaceutical products (Vicodin, Xanax, and Zoloft) selected for their frequency of prescription, treatment class and range of chemical structures.
4. Product Use, Placement, and Safety Evaluation. Product evaluated for ease of operation and target user safety from harmful exposure throughout entire deactivation process. Aim will also assess different ways product will be distributed to consumers.
5. Preliminary Design for Phase II Prototype. Focus on designing device prototype for Phase II and product cost analyses to demonstrate feasibility of proposed deactivation device for Phase II scale-up.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
SBIR FAST-TRACK AWARD (PHASE I STUDY BASE REQUIREMENT WITH OPTION FOR PHASE II STUDY) CONTINUOUS MONITORING OF ALCOHOL USE BY WEARABLE BIOSENSORS
-
批准号:10551065
-
项目类别:
-
资助金额:$199.97万
-
财政年份:2020
-
负责人:BADAWI DWEIK
-
依托单位:
SBIR FAST-TRACK AWARD (PHASE I STUDY BASE REQUIREMENT WITH OPTION FOR PHASE II STUDY) CONTINUOUS MONITORING OF ALCOHOL USE BY WEARABLE BIOSENSORS
-
批准号:10272782
-
项目类别:
-
资助金额:$50.0万
-
财政年份:2020
-
负责人:BADAWI DWEIK
-
依托单位: